Patents by Inventor Anna M. Ericsson

Anna M. Ericsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8008481
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: August 30, 2011
    Inventors: Anna M. Ericsson, Andrew Burchat, Kristine E. Frank, David J. Calderwood, Lily K. Abbott, Maria A. Argiriadi, David W. Borhani, Kevin P. Cusack, Richard W. Dixon, Thomas D. Gordon, Kelly D. Mullen, Robert V. Talanian, Xiaoyun Wu, Xiaolei Zhang, Lu Wang, Biqin Li, Claude E. Barberis, Neil Wishart
  • Publication number: 20110190489
    Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2010
    Publication date: August 4, 2011
    Applicant: Abbott Laboratories
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan R. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller, Eric C. Breinlinger, Kelly D. Mullen, Gagandeep Somal
  • Publication number: 20110178096
    Abstract: The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.
    Type: Application
    Filed: March 29, 2011
    Publication date: July 21, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Dawn M. George, Lu X. Wang, Biqin Li, Anna M. Ericsson, Graham K. Ansell
  • Publication number: 20110152243
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 23, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Neil Wishart, Theresa Dunstan, Jeremy J. Edmunds, Anna M. Ericsson, Catherine R. Ferenz, Adrian D. Hobson, David C. Ihle, Kent D. Stewart, Lei Wang, Lu Wang
  • Patent number: 7939544
    Abstract: The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: May 10, 2011
    Assignee: Abbott Laboratories
    Inventors: Dawn M. George, Lu Wang, Biqin Li, Anna M. Ericsson, Graham K. Ansell
  • Publication number: 20090312338
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 17, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • Publication number: 20090286784
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: July 22, 2009
    Publication date: November 19, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Yujia Dai, Steven K. Davidsen, Anna M. Ericsson, Kresna Hartandi, Zhiqin Ji, Michael R. Michaelides
  • Patent number: 7598283
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: October 6, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Yujia Dai, Steven K. Davidsen, Anna M. Ericsson, Kresna Hartandi, Zhiqin Ji, Michael R. Michaelides
  • Publication number: 20090118298
    Abstract: The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.
    Type: Application
    Filed: September 25, 2008
    Publication date: May 7, 2009
    Inventors: Dawn M. George, Lu Wang, Biqin Li, Anna M. Ericsson, Graham K. Ansell
  • Patent number: 7468371
    Abstract: Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: December 23, 2008
    Assignee: Abbott Laboratories Inc.
    Inventors: Lee D. Arnold, J├╝rgen Dinges, Richard W. Dixon, Stevan W. Djuric, Anna M. Ericsson, Kimba Fischer, Alan F. Gasiecki, Vijaya J. Gracias, James H. Holms, Makoto Takeshita, Michael R. Michaelides, Melanie A. Muckey, Paul Rafferty, Douglas H. Steinman, Carol K. Wada, Zhiren Xia, Irini Akritopoulou-Zanze, Henry Q. Zhang
  • Patent number: 7297709
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: November 20, 2007
    Assignee: Abbott Laboratories
    Inventors: Yujia Dai, Steven K. Davidsen, Anna M. Ericsson, Kresna Hartandi, Zhiqin Ji, Michael R. Michaelides
  • Patent number: 7091227
    Abstract: The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: August 15, 2006
    Assignee: Abbott GmbH & Co. KG
    Inventors: Barbara Scott, Lee D. Arnold, Anna M. Ericsson, Kevin P. Cusack
  • Publication number: 20040235892
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: May 22, 2003
    Publication date: November 25, 2004
    Inventors: Yujia Dai, Steven K. Davidsen, Anna M. Ericsson, Kresna Hartandi, Zhiqin Ji, Michael R. Michaelides
  • Publication number: 20030153568
    Abstract: The present invention is directed to a compound of formula (I), 1
    Type: Application
    Filed: February 6, 2001
    Publication date: August 14, 2003
    Applicant: BASF Aktiengesellschaft Ludwigshafen, Germany
    Inventors: Kevin P. Cusack, Barbara Scott, Lee D. Arnold, Anna M. Ericsson
  • Patent number: 6462036
    Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: October 8, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Kevin J. Doyle, Paul Rafferty, Robert W. Steele, David J. Wilkins, Lee D. Arnold, Michael Hockley, Anna M. Ericsson, Nobuhiko Iwasaki, Nobuo Ogawa